After 40 years of research in Hungary, the developed vaccine is able to prevent and treat atherosclerosis. In addition, this immunization prevents atherosclerosis from coming back after treatment is done.
The vaccine, named J for H (Jab for Health) offers an immunization procedure which balances the production of anticholesterol antibodies in the organism. The most important characteristic of this practice is that J for H does not leave negative side effects. Dr. István Horváth is involved (and the owner) in the entire production process for this treatment; it contains natural products and substances found inside our organism.
Since the first human immunization (2005, Hungary) saving over ten thousand human lives from 30 countries around the world including USA, Germany, Norway, Spain, Israel, Australia, Romania and Russia.
The cholesterol antigen’s ingredient is a highly purified and substituted cholesterol base “artificial bacteria”. The structure of the antigen particles are within a micrococcus size (200-400 nm).
After 4 years storage in refrigerator (+5 °C) the physical behavior of the antigen did not change. The particles were not agglutinated, their suspending and microscopic morphology was not changed. The grape-form agglutination was preventable by physiological intermixture.
The vaccine consists of cholesterol antigens that are mixed with the patient’s blood serum. As a result, the injection of this substances makes the patient’s organism to gives an “immune answer” by increasing the production of anticholesterol antibodies.
At the start of the sclerotization the titre of ACHA is decreasing. As a conseguence of it more and more apo-B joins to the LDL particula, hampering the utilization of the cholesterol. Even the cholesterol level is high in the blood, a “cholesterol starvation” is appearing, forcing the cholesterol production by the feedback mechanism. As a consequence of the immunization this self-inducing phenomenon is turning back.
Producing more and more ACHA and fixing to the cholesterol molecules at the surface of the LDL is blocking the apo-B fixation to the particula and helping the fixation of the particulas to the cell receptors. The decrease of the cholesterol level in the blood starts up the mobilization and utilization of the depo-cholesterol of the placks. The growing cholesterol utilization is forcing the bile production and as a consequence of it helps the removal of the cholesterol. More than 90 percent of the cholesterol is applied to bile production, it is almost the only quantum and possibility to remove the cholesterol from the body while an important part of the bile acids return to the circulation.
The raising of the production of ACHA can be doubly favorable with ensuring a smooth blood streaming and using the cholesterol, liberated from the plaques. It is important to mention that fully closed blood streams have very low chance of being cured, as there is little or no blood flow that could transmit the effect of the immunization ( like the closed room that cannot be cleaned form the outside). Consequently, it is very important to get the preventive immunization therapy as soon as possible.)
1 mg particule /ml phisiological solution plus 0,1 ml self-serum added in each case by intravenous injection. The immunization procedure consists of a six week injection treatment (9 shots).
On the first week 3 injections are given, then the second week consists of 2 shots and then weekly injections follow until the end of the treatment. Patients coming from overseas are required to stay a minimum of one week in Budapest, Hungary but are advised to stay 2 weeks for the first 5 shots; this is the most important part of the immunization process as the vaccine will induce producing the ACHA.
Subsequently, patients can choose to return home and finish their treatment with their own personal doctor; the last four weeks of the treatment stabilize the organism for self-supporting continuous production of the anticholesterol antibodies.
Unfortunately, there are some patients that are advised not to undergo through the J for H treatment. There are cases when there is no reason to immunize, because the organism can’t answer for it:
Horváth I.: OBNI Budapest 1986; Orvosi Hetilap 1989. National Institute of Derm.Vener.
Horváth I. – Bertók L.: J. C. Sugárbiológiai Intézet; 1992. MTA előadás 2000.
Horváth I. – Szende B-Kovács Á. I. sz. Kórbonctani és Rákkutató 1994. Medical Science Monitor 1994.
Horváth I. – Dávid Á.: Gyógyszer Ellenőrző Laboratórium 1999, Central Inst. of Drugcontrol Budapest
Horváth I. – Paulin F.: Budapest, SE Szülészeti Nőgyógyászati Klin. -Magán állatház 2003. MIT congress Szeged 2004.